Patents by Inventor John E. MacNair

John E. MacNair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108742
    Abstract: The present invention provides a method of producing a polysaccharide—protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 4, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael Albert Winters, John E. MacNair
  • Patent number: 11883502
    Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael Albert Winters, John E. MacNair
  • Publication number: 20220088210
    Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Albert Winters, John E. MacNair
  • Patent number: 11219680
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or more Steptococcus pneumoniae serotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more different Steptococcus pneumoniae serotypes are conjugated to one or more other carrier proteins.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 11, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. MacNair, Michael A. Winters, Thomas Svab, Sheng-Ching Wang, William J. Smith, Cecilia Giovarelli
  • Publication number: 20210330777
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.
    Type: Application
    Filed: July 7, 2021
    Publication date: October 28, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jian He, John E. MacNair, William J. Smith, Michael A. Winters, Joseph G. Joyce, Chitrananda Abeygunawardana, Luwy Musey, Hari Pujar, Julie M. Skinner, Patrick McHugh
  • Publication number: 20210330778
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.
    Type: Application
    Filed: July 7, 2021
    Publication date: October 28, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jian He, John E. MacNair, William J. Smith, Michael A. Winters, Joseph G. Joyce, Chitrananda Abeygunawardana, Luwy Musey, Hari Pujar
  • Patent number: 11090374
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: August 17, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian He, John E. MacNair, William J. Smith, Michael A. Winters, Joseph G. Joyce, Chitrananda Abeygunawardana, Luwy Musey, Hari Pujar, Julie M. Skinner, Emily Wen, Patrick McHugh, John Michael Williams, Catherine Lancaster
  • Publication number: 20200222550
    Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
    Type: Application
    Filed: January 30, 2018
    Publication date: July 16, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Albert Winters, John E. MacNair
  • Publication number: 20200061179
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or more Streptococcus pneumoniae serotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more different Streptococcus pneumoniae serotypes are conjugated to one or more other carrier proteins.
    Type: Application
    Filed: February 20, 2018
    Publication date: February 27, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John E. MacNair, Michael A. Winters, Thomas Svab, Sheng-Ching Wang, William J. Smith, Cecilia Giovarelli
  • Publication number: 20200054733
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.
    Type: Application
    Filed: February 20, 2018
    Publication date: February 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jian He, John E. MacNair, William J. Smith, Michael A. Winters, Joseph G. Joyce, Chitrananda Abeygunawardana, Luwy Musey, Hari Pujar, Julie M. Skinner, Emily Wen, Patrick McHugh, John Michael Williams, Catherine Lancaster